Pacira BioSciences Inc
(STU:82P)
€
22.8
-0.60 (-2.56%)
Market Cap: 901.83 Mil
Enterprise Value: 1.08 Bil
PE Ratio: 220.08
PB Ratio: 1.59
GF Score: 75/100 Pacira Biosciences Inc at Goldman Sachs Healthcare Conference Transcript
Jun 08, 2026 / 05:20PM GMT
Release Date Price:
€20
(+2.04%)
Matthew Dellatorre
Goldman Sachs - Analyst
Good afternoon, everyone, and thank you for joining us. My name is Matt Dellatorre. I'm a biopharma analyst here at Goldman Sachs. And we're very pleased to continue the next session this afternoon with Pacira BioSciences, where I'm joined by the company's CEO, Frank Lee.
Frank, thank you for being here.
Frank Lee
Pacira Biosciences Inc - Chief Executive Officer, Director
Thanks for the kind invitation.
Questions & Answers
Matthew Dellatorre;Frank Lee
Goldman Sachs - Analyst;Pacira Biosciences Inc - Chief Executive Officer, Director
Frank, maybe to start, just to get everyone up to speed before we dive into some of the specific programs, maybe for those less familiar with Pacira give us a brief overview of the company? And then maybe frame for us where you all stand today, what your key priorities are? And then how you're thinking about the outlook and strategy for the company as we head into second half and beyond.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot